In our latest blog post, our CEO, Andy Scharenberg reflects on his experience as a panelist at #SXSW2024 and details his goal of advancing practice-changing #CellTherapies. Read more about his panel, “From Adversary to Ally: Reimagining Viruses As Medicines” here: https://lnkd.in/g9J8RZFB #MedicinesGoViral
Umoja Biopharma
Pharmaceutical Manufacturing
Seattle, WA 14,951 followers
Next Generation Immunotherapies
About us
Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Seattle, WA
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
1920 Terry Avenue
Seattle, WA 98101, US
Employees at Umoja Biopharma
Updates
-
Here at Umoja, our world-class team is united by our shared goal of unlocking the true potential of #CART cell therapies. We're recognizing #WorldBloodCancerDay by sharing our commitment to extending the benefits of #immunotherapy to every patient bearing the burden of #cancer.
-
We're proud to announce that Umoja scientist Ashley Yingst abstract on Synthetic Receptor Enabled Differentiation (ShRED) received the ISCT, International Society for Cell & Gene Therapy Stem Cell Engineering Abstract Award. This recognition reflects Umoja’s commitment to advancing "off-the-shelf" #Immunotherapies. More on this prestigious award: https://bit.ly/3y8QPak
-
Our CEO, Andy Scharenberg, MD was recently featured on an episode of the Talking Biotech podcast with Dr. Kevin Folta! Listen to the episode to learn how Umoja is engineering #CARTcells #InVivo to create more effective #CellTherapies: https://lnkd.in/gMADtcUJ
-
Umoja will present at the 27th American Society of Gene & Cell Therapy Annual Meeting! We are excited to attend alongside other industry leaders and present pharmacokinetics data regarding our #VivoVec platform. Read the abstract here: https://bit.ly/3JJlCgp #ASGCT2024
-
Earlier this month, we had the honor of touring another group of #biotech’s next generation of ambitious scientists and engineers around The CLIMB as part of our continued engagement and partnership with the Colorado BioScience Institute mentorship program. Thank you to Chelsea Johansen, Jillian Collins, Samuel Saccomano, and Tyler Sodia for coming to learn about how we’re bringing Umoja’s #CGT vision to life at The CLIMB to enable bringing innovative products to patients.
-
For #NationalVolunteerWeek, we're highlighting the great work Umojians are doing to shine light on #STEM careers all over Seattle and in Colorado. Thank you, Alessandra Sullivan, for your work connecting Umoja with young talent so we can guide them to a new world of opportunity. #GlobalVolunteerMonth
-
Umoja will present at Cell & Gene Meeting on the Med! Our COO, David Fontana, will be participating in the Company Presentations on Wednesday, April 10. The presentation will be streamed for virtual attendees. Learn more here: https://lnkd.in/dathw_2
-
Our CEO, Andy Scharenberg MD, CAR T pioneer Carl H. June, MD, and Stephen Russell, MD, PhD will be in New York City for the Alliance for Cancer Gene Therapy Summit 2024 tomorrow to share insights on the progress and challenges of in vivo cell and gene therapy. Learn more here: https://brnw.ch/21wIj8a
-
Our CEO, Andy Scharenberg, will present a corporate overview at the H.C. Wainwright & Co., LLC 2nd Annual Cell Therapy Virtual Conference on March 26. Members of our leadership team will also be available for one-on-one meetings during the conference. More details on the presentation and how to schedule a meeting here: https://lnkd.in/gSZ8Tu8e
Umoja Biopharma to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
https://www.umoja-biopharma.com